Print
schelsinger koltan

Koltan Co-founder
Dr. Joseph Schlessinger recently revealed a “breakthrough in underatanding the genetics of uterine and ovarian cancers.”

HAMPTON, N.J.,  NEW HAVEN,- Celldex Therapeutics, Inc. (NASDAQ:CLDX) has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, Inc., a privately owned clinical-stage company focused on the discovery and development focused primarily on drugs to treat Cancer.

Kolltan has previously reported clinical and preclinical data that its drug candidates “can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors and seen in patients who have failed other cancer therapies.”

Kolltan co-founder  Dr. Joseph Schlessinger, is the William H. Prusoff Professor of Pharmacology; Chair, Pharmacology; Co-Director, Cancer Biology Institute at Yale University School of Medicine.. Early this fall Schlesinger’s lab revealed a major breakthrough for ovarian and uterine cancers, defining the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.